SCHEMBL3011840

SCHEMBL3011840

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
DPP8 Q6V1X1 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
MAPK1 P28482 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
EPHX2 P34913 1/20 0.36
FABP4 P15090 3/20 0.35
OGA O60502 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
KDM4E B2RXH2 1/20 0.33
LPAR1 Q92633 1/20 0.33
LPAR2 Q9HBW0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654029 0.95 FABP4 (0.36) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3018377 0.91 ALDH1A1 (0.40) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3011364 0.89 LMNA (0.38) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3013519 0.89 OGA (0.39) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3008179 0.88 DPP8 (0.39) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3013070 0.88 CACNA1G (0.44) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3006975 0.88 FABP4 (0.42) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3015370 0.88 ALDH1A1 (0.41) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3015626 0.88 MEN1 (0.44) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB
SCHEMBL3019563 0.87 ALDH1A1 (0.38) ALDH1A1DPP8PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885DPP8 1183/4885PIK3CD 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.